DIA: Driving Insights to Action
Science:Life Sciences
In March 2019, the Health Ministry of India released new guidelines for clinical research. What is the state of pre-market and post-market safety for patients and drugs in India, six months after these new guidelines were announced? Dr. Srikanth Krishnamurthy, a consulting pulmonologist at Sri Bala Medical Centre and Hospital, discusses the pre-market clinical research safety perspective; and Dr. J. Vijay Venkatraman, Managing Director and CEO at Oviya MedSafe, contributes the perspective of post-market drug safety in India.
More Episodes
DIA/Tufts CSDD Research: AI Saving Time in Drug Development
2025-01-17
358
2025-01-17
358
DIA: Your Partner in Life Sciences Training and Development
2024-11-06
255
2024-11-06
255
GPP Experts Explain Authorship Algorithm
2024-04-23
272
2024-04-23
272
"Dossier in the Cloud" Democratizing Global Access
2024-04-02
314
2024-04-02
314
DIA: A Place Where You Can Make a Difference
2024-03-28
253
2024-03-28
253
Retiring TGA Head Maps Australia’s Post-Pandemic Future
2023-07-17
395
2023-07-17
395
Patient Engagement: Evolution of Who Knows What, Part 2
2023-06-14
286
2023-06-14
286
Patient Engagement: Evolution of Who Knows What, Part 1
2023-06-12
428
2023-06-12
428
Rwanda Welcomes African Medicines Agency Home
2022-11-30
603
2022-11-30
603
Will Technology Solve the Research “People Problem”?
2022-11-22
376
2022-11-22
376
Why Trans/Nonbinary Research Benefits All Communities
2022-11-18
493
2022-11-18
493
Digital Revolutionizing Data-Driven Reimbursement
2022-10-20
402
2022-10-20
402
China Sets New Record for Local Drug Approvals in 2021
2022-09-15
435
2022-09-15
435
WHO Pilot Formalizes CSA Process to Assist Developers
2022-08-02
427
2022-08-02
427
Get this podcast on your
phone, FREE
